• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Pegvisomant in the treatment of acromegaly.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Parkinson, Craig
    Scarlett, J A
    Trainer, Peter J
    Affiliation
    Department of Endocrinology, Christie Hosptial, Wilmslow Road, Manchester M20 4BX, UK.
    Issue Date
    2003-09-26
    
    Metadata
    Show full item record
    Abstract
    Epidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date.
    Citation
    Pegvisomant in the treatment of acromegaly. 2003, 55 (10):1303-14 Adv. Drug Deliv. Rev.
    Journal
    Advanced Drug Delivery Reviews
    URI
    http://hdl.handle.net/10541/78905
    DOI
    10.1016/S0169-409X(03)00111-X
    PubMed ID
    14499709
    Type
    Article
    Language
    en
    ISSN
    0169-409X
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0169-409X(03)00111-X
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The place of pegvisomant in the management of acromegaly.
    • Authors: Parkinson C, Trainer PJ
    • Issue date: 2001 Sep
    • Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
    • Authors: Paisley AN, Trainer P, Drake W
    • Issue date: 2004 Mar
    • [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
    • Authors: Zgliczyński W, Zdunowski P
    • Issue date: 2007 Sep-Oct
    • Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    • Authors: Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G
    • Issue date: 2008 Aug
    • Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
    • Authors: Parkinson C, Trainer PJ
    • Issue date: 2000 Apr
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.